Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Blood blood.2025029572.

https://doi.org/10.1182/blood.2025029572

Published: 2025

Includes: Supplemental data

Journal Articles

SKP2/CKS1B as a rational drug target in 1q21 amplified multiple myeloma.

Fei Liu, Carmen Vicente, Elena Ruiz, Christian Pacifico, Geoff Nelson, Marta Larrayoz, Jose A. Martinez-Climent, Andrew Bloecher

Blood (2025) 146 (Supplement 1): 2169.

https://doi.org/10.1182/blood-2025-2169

Published: 2025

Journal Articles

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

Blood (2025) 146 (Supplement 1): 916.

https://doi.org/10.1182/blood-2025-916

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation

Blood (2025) 146 (Supplement 1): 3539.

https://doi.org/10.1182/blood-2025-3539

Published: 2025

Journal Articles

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Blood (2024) 144 (Supplement 1): 670.

https://doi.org/10.1182/blood-2024-194041

Published: 2024

Journal Articles

Genomic and Single Cell Investigation of MRD Clonality in Genetically Engineered Mouse Models of Multiple Myeloma

Junfei Zhao, Marta Larrayoz, Chad C. Bjorklund, Anita K. Gandhi, Jose A. Martinez-Climent, Patrick R. Hagner, Maria Ortiz

Blood (2024) 144 (Supplement 1): 1409.

https://doi.org/10.1182/blood-2024-210958

Published: 2024

Journal Articles

Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Blood (2024) 144 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2024-209833

Published: 2024

Journal Articles

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Blood (2024) 144 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2024-201435

Published: 2024

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Jon Celay, Miriam Recalde, María Victoria Revuelta, Marta Larrayoz, Sara Rodriguez, Maria J Garcia-Barchino, Jennifer R. Chapman-Fredricks, Teresa Lozano, Juan J Lasarte, Ming Q. Du, Izidore S. Lossos, Sergio Roa, Aldo Roccaro, Miguel Canales, Felipe Prosper, Bruno Paiva, Leandro Cerchietti, Jose A. Martinez-Climent

Blood (2023) 142 (Supplement 1): 431.

https://doi.org/10.1182/blood-2023-173394

Published: 2023

Journal Articles

Lymphoma-Derived IL-10 Is a Key Immunomodulatory Factor at the Tumor Microenvironment of Activated B-Cell Diffuse Large B-Cell Lymphoma and Influences In Vivo Responses to Immunotherapy

Marcos Garcia-Lacarte, Sara C Grijalba, Francisco J Novo, Adrián Arnaiz-Leché, Javier Melchor, Marién Pascual, Enrique Goñi, Sandra Morales-Sánchez, María A Burrell, Oscar Blanco, Iñigo Clemente-Larramendi, Jose A Martinez-Climent, Noelia Casares, Juan J Lasarte, Pablo Sarobe, Miguel Canales, Sergio Roa

Blood (2023) 142 (Supplement 1): 716.

https://doi.org/10.1182/blood-2023-177612

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Irene Peris, Silvia Romero-Murillo, Elena Martínez-Balsalobre, Caroline C. Farrington, Elena Arriazu, Nerea Marcotegui, Marta Jiménez-Muñoz, Cristina Alburquerque-Prieto, Andrea Torres-López, Vicente Fresquet, Jose A. Martínez-Climent, Maria C. Mateos, Maria L. Cayuela, Goutham Narla, Maria D. Odero, Carmen Vicente

Blood (2023) 141 (9): 1047–1059.

https://doi.org/10.1182/blood.2022016466

Published: 2023

Includes: Supplemental data

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

Blood (2015) 125 (12): 1922–1931.

https://doi.org/10.1182/blood-2014-08-596247

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies

Edurne San José-Enériz, PhD, Xabier Agirre, PhD, Obdulia Rabal, PhD, Sergio Roa, PhD, Amaia Vilas-Zornoza, PhD, Estíbaliz Miranda, Ana Ugarte, PhD, Juan Antonio Sanchez-Arias, PhD, Bruno Paiva, PhD, Jesus F. San Miguel, Jose A. Martinez-Climent, MD PhD, Julen Oyarzabal, PhD, Felipe Prosper, MD

Blood (2014) 124 (21): 3532.

https://doi.org/10.1182/blood.V124.21.3532.3532

Published: 2014

Journal Articles

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

Vicente Fresquet, Melissa Rieger, Carlo Carolis, Maria J. García-Barchino, Jose A. Martinez-Climent

Blood (2014) 123 (26): 4111–4119.

https://doi.org/10.1182/blood-2014-03-560284

Published: 2014

Includes: Supplemental data

Journal Articles

Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes

Blood (2013) 122 (21): 77.

https://doi.org/10.1182/blood.V122.21.77.77

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

SKP2/CKS1B as a rational drug target in 1q21 amplified multiple myeloma.

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Genomic and Single Cell Investigation of MRD Clonality in Genetically Engineered Mouse Models of Multiple Myeloma

Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Lymphoma-Derived IL-10 Is a Key Immunomodulatory Factor at the Tumor Microenvironment of Activated B-Cell Diffuse Large B-Cell Lymphoma and Influences In Vivo Responses to Immunotherapy

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only